We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00585962
First Posted: January 4, 2008
Last Update Posted: September 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
American College of Radiology Imaging Network
Information provided by (Responsible Party):
Anthony Laurence Zietman, MD, Massachusetts General Hospital
  Purpose
The primary purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. This study will also gather data to determine the ability of the proton beam to eradicate prostate cancer. Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam.

Condition Intervention Phase
Prostate Cancer Radiation: Proton Beam Radiation Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study Using Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate

Resource links provided by NLM:


Further study details as provided by Anthony Laurence Zietman, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • To assess the late morbidity of 82 GY delivered to the prostate and surrounding tissues using proton beam radiation [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • To assess the acute morbidity following protocol treatment and to determine the ability of this treatment to control cancer. [ Time Frame: 3 years ]

Enrollment: 57
Study Start Date: February 2004
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Radiation: Proton Beam Radiation
    Once a day, 5 days a week (Monday-Friday), for 8 weeks.
Detailed Description:
  • Radiation therapy to the pelvis and prostate will be given once a day, 5 days a week (Monday-Friday), for 8 weeks. Each treatment takes about 10-20 minutes.
  • Participants will be seen once a week for the entire 8 weeks by their study doctor to monitor and record any side effects. At the end of radiation therapy, participants will have a history and physical examination. Follow-up visits with the study doctor will be done at weeks 13 and 26 and then every 6 months for 3 years, then annually to year five.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with previously treated adenocarcinoma of the stages T1c-T2b and Gleason of equal to or greater than 5.
  • PSA values of equal to or less than 15 ng/ml must be demonstrated within two months prior to study entry and greater than 3 weeks after prostate biopsy.
  • Zubrod status 0-1.
  • No evidence of distant metastasis.
  • No evidence of other cancer. Prior malignancy does not exclude the patient if disease free for greater than five years.

Exclusion Criteria:

  • Clinical stages T2c or above.
  • PSA greater than 15.
  • Any patient with T1c disease, a PSA less than or equal to 4 and Gleason sum less than 6.
  • Evidence of lymph node involvement if lymph node sampling performed.
  • Previous prostate surgery to include: simple prostatectomy, TURP, hyperthermia and cryosurgery.
  • Previous prostate radiation.
  • Prior hormonal therapy.
  • History of inflammatory bowel disease even if currently inactive or controlled on medication.
  • Prior systemic chemotherapy.
  • History of proximal urethral stricture requiring dilatation.
  • Current and continuing anticoagulation with Coumadin or equivalent.
  • Major medical or psychiatric illness
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00585962


Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
American College of Radiology Imaging Network
Investigators
Principal Investigator: Anthony Zietman, MD Massachusetts General Hospital
  More Information

Responsible Party: Anthony Laurence Zietman, MD, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00585962     History of Changes
Other Study ID Numbers: 02-064
First Submitted: December 27, 2007
First Posted: January 4, 2008
Last Update Posted: September 5, 2017
Last Verified: August 2017

Keywords provided by Anthony Laurence Zietman, MD, Massachusetts General Hospital:
proton beam radiation

Additional relevant MeSH terms:
Adenocarcinoma
Prostatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases